

Opiate Dependence Agents (40)

Point-of-Sale (POS) edits are safety limitations that are automatically verified through computer programming at the time that a prescription claim is submitted at the pharmacy. These edits can be applied to *any* medication, whether or not it is listed in the Preferred Drug List / Non-Preferred Drug List (PDL/NPDL). The first section of this document is organized to follow the order of the therapeutic classes in the PDL/NPDL and explains the POS edits for those medications.

POS Abbreviations

AL – Age Limit	DD – Drug-Drug Interaction	MD – Maximum Dose Limit	TD - Therapeutic Duplication
BH – Behavioral Health Clinical Authorization for Children Younger than 7 Years of Age	DS Maximum Days' Supply Allowed	PR – Enrollment in a Physician-Supervised Program Required	UN – Drug Use Not Warranted
BY – Diagnosis Codes Bypass Some Requirements	DT – Duration of Therapy Limit	PU – Prior Use of Other Medication is Required	X – Prescriber Must Have 'X' DEA Number
CL – Additional Clinical Information is Required	DX – Diagnosis Code Requirement	QL – Quantity Limit	YQ – Yearly Quantity Limit
CU – Concurrent Use with Other Medication is Restricted	ER – Early Refill	RX – Specific Prescription Requirement	

Pharmacy Prior Authorization Phone Numbers for MCOs and FFS

Aetna Better Health of Louisiana **1-855-242-0802**

AmeriHealth Caritas Louisiana **1-800-684-5502**

Fee-for-Service (FFS) Louisiana Legacy Medicaid **1-866-730-4357**

Healthy Blue **1-844-521-6942**

Louisiana Healthcare Connections **1-888-929-3790**

UnitedHealthcare **1-800-310-6826**

Opiate Dependence Agents (40)

POS Edits		
AL – The agents listed in the table to the right are limited to use in recipients who meet specific age requirements.	Minimum Age Requirements	
	Generic (Brand Example)	Minimum Age
	Buprenorphine (Probuphine®)	16 years
	Buprenorphine (Sublocade®)	18 years
	Buprenorphine SL	16 years
	Buprenorphine/Naloxone (Bunavail®, Suboxone®, Zubsolv®)	16 years
	<u>Lofexidine (Lucemyra®)</u>	<u>18 years</u>
	Naltrexone <u>Extended-Release Injectable Suspension</u> (Vivitrol®)	18 years
		<u>18 years</u>
CU – <u>Concurrent</u> Incoming prescriptions will deny when the recipient has an active prescription on file for another agent. An active prescription is a prescription in which the days' supply has not expired.		
<ul style="list-style-type: none"> - <u>Concurrent</u> opioid analgesic, benzodiazepine and/or any buprenorphine-containing agent prescriptions will deny. - <u>Concurrent buprenorphine containing agents and naltrexone prescriptions will deny.</u> 		
DD – Pharmacy claims for <u>naltrexone tablets</u> or naltrexone extended-release injectable suspension (Vivitrol®) will deny for drug-drug interaction when the recipient has an active prescription (a prescription in which the days' supply has not expired) for an opioid.		
DS – <u>Pharmacy claims for lofexidine tablets are limited to a 14-day supply per 6-month period.</u>		
DX – Pharmacy claims for some agents must be submitted with an appropriate diagnosis code.		
<ul style="list-style-type: none"> - <u>Pharmacy claims for all buprenorphine opiate dependence agents (single-ingredient and combination) must be submitted with a diagnosis code for opioid dependence (F11.2*).</u> - <u>Pharmacy claims for lofexidine (Lucemyra®) must be submitted with a diagnosis code for ONE of the following:</u> <ul style="list-style-type: none"> <input type="radio"/> <u>Opioid abuse with withdrawal – F11.13</u> <input type="radio"/> <u>Opioid dependence with withdrawal – F11.23</u> <input type="radio"/> <u>Opioid use, unspecified with withdrawal – F11.93</u> - <u>Naltrexone</u> <u>Pharmacy claims for naltrexone tablets or naltrexone</u> extended-release injectable suspension (Vivitrol®) must be submitted with either a diagnosis code for opioid dependence (F11.2*) or alcohol dependence (F10.2*). 		
<p>*Any number or letter or combination of UP TO FOUR numbers and letters of an assigned ICD-10-CM diagnosis code</p>		

POS Edits

MD – The following agents are limited to a maximum daily dose:

- Buprenorphine agents (single-ingredient and combination) are limited to a maximum daily dose of 24mg per day of buprenorphine or buprenorphine equivalent. Refer to specific product prescribing information for buprenorphine equivalence charts
- Lofexidine 0.18mg tablet is limited to a maximum daily dose of 2.88mg .-(16 tablets)

	Quantity Limits	
	Generic (Brand Example)	Quantity Limit
QL – Some agents have quantity limits as listed in the chart to the right.	Buprenorphine Implant Kit (Probuphine®)	2 kits/720 days
	Buprenorphine Extended-Release Injection (Sublocade®)	1 unit/30 days
	Buprenorphine SL Tablet 2mg	2 units/day
	Buprenorphine SL Tablet 8mg	3 units/day
	Buprenorphine/Naloxone 2.1mg/0.3mg (Bunavail®)	1 unit/day
	Buprenorphine/Naloxone 4.2mg/0.7mg (Bunavail®)	3 units/day
	Buprenorphine/Naloxone 6.3mg/1mg (Bunavail®)	2 units/day
	Buprenorphine/Naloxone 2mg/0.5mg SL Tab (Suboxone®)	2 units/day
	Buprenorphine/Naloxone 2mg/0.5mg SL Film (Suboxone®)	1 unit/day
	Buprenorphine/Naloxone 4mg/1mg SL Film (Suboxone®)	1 unit/day
	Buprenorphine/Naloxone 8mg/2mg SL Film/Tab (Suboxone®)	3 units/day
	Buprenorphine/Naloxone 12mg/3mg SL Film (Suboxone®)	2 units/day
	Buprenorphine/Naloxone SL Tablet 0.7mg/0.18mg (Zubsolv®)	1 unit/day
	Buprenorphine/Naloxone SL Tablet 1.4mg/0.36mg (Zubsolv®)	1 unit/day
	Buprenorphine/Naloxone SL Tablet 2.9mg/0.71mg (Zubsolv®)	1 unit/day
	Buprenorphine/Naloxone SL Tablet 5.7mg/1.4mg (Zubsolv®)	3 units/day
	Buprenorphine/Naloxone SL Tablet 8.6mg/2.1mg (Zubsolv®)	2 units/day
	Buprenorphine/Naloxone SL Tablet 11.4mg/2.9mg (Zubsolv®)	1 unit/day
	Lofexidine 0.18mg Tablet (Lucemyra®)	16 units/day
	Naltrexone Extended-Release Injectable Suspension (Vivitrol®)	1 unit/28 days
	Naloxone Nasal Spray (Narcan®)	2 units/90 days
	Naloxone Injectable Solution/Cartridge 0.4mg/ml	2 units/90 days
	Naloxone Injectable Solution Syringe 1mg/ml	2 units/90 days
	Naloxone Injectable Solution (5ml, 10ml, 20ml) 1mg/ml	1 unit/90 days
	Naloxone Injectable Solution (10ml) 0.4mg/ml	1 unit/90 days

POS Edits

TD – These agents are monitored at the pharmacy POS for duplication of therapy with each other.~~– with opioid analgesics, and with benzodiazepines.~~

- Incoming prescriptions for buprenorphine or buprenorphine/naloxone agents will deny when the recipient has an active prescription (a prescription in which the days' supply has not expired) for any buprenorphine or buprenorphine/naloxone agent. ~~Concurrent opioid analgesic and/or benzodiazepine prescriptions will deny for recipients with an active buprenorphine or buprenorphine/naloxone prescription (a prescription in which the days' supply has not expired).~~
- [Incoming prescriptions for any naltrexone agent will deny when the recipient has an active prescription for any other naltrexone agent.](#)

X – Prescribers of buprenorphine must meet enrollment and certification requirements.

Revision	Date
Created POS Document	February 2020
Updated age for BH in POS Abbreviations chart	November 2020
<u>Added POS edits for lofexidine and naltrexone</u>	<u>January 2021</u>